Biocannabix Announces LOI for Pediatric Cannabis Research

Biocannabix Announces LOI for Pediatric Cannabis Research

By: Tomas Ronolski - News

Thursday, April 29, 2021

Cannabis is being used today for reasons as diverse as pain control to regulating seizures. Long gone are the days of cannabis only seen as a narcotic, and a scourge in society. Today, shares of a Canadian company surged after announcing a partnership that plans on expanding studies within pediatric applications. 

Biocannabix Health Corporation, a wholly-owned subsidiary of Relevium Technologies Inc. (TSX-Venture:RLV) is focusing on pediatric and geriatric applications of Cannabinoid nutraceutical and medical food formulations. This partnership will allow Biocannabix 51% equity interest in the combined research entity with German-based IAM Health GmbH.

IAM Health GmbH develops new treatments for autoimmune conditions, including the study of the role of certain cannabinoids, primarily for the development of therapies for pediatric applications. Biocannabix will benefit from a realigned direction that focuses on the pediatric cannabinoid space.

Shares of Relevium have fallen from higher levels earlier this year, but news of the partnership sent the stock up 20% in early-afternoon trading.  

Copyright © 2021 All rights reserved. Republication or redistribution of's content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Canadian Payment Firm Jumps on Crypto-to-Fiat Bridge
Slipknot and Cannabis Company Launch Special Edition Packs
Shares of Luxury Retailer Pop on Mothers Day Sales
Most Popular
FREE Newsletter

Back to Top